Abstracts Archive - Page 2004 of 2425 - ACR Meeting Abstracts

Abstract Number: 704 • 2014 ACR/ARHP Annual Meeting
Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort
Ruba Kado¹, Emily Siegwald², Emily Lewis², Mitch Goodsitt³, Emmanuel Christodoulou³, Ella Kazerooni³ and W. Joseph McCune⁴, ¹Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Ionizing radiation from CT scanning can increase cancer risk. Lupus patients are frequently evaluated for chest pain and may have multiple pulmonary embolism CT…
Abstract Number: 703 • 2014 ACR/ARHP Annual Meeting
Autoimmune Hepatitis in Systemic Lupus Erythematosus
Doo-Ho Lim, Seung-Hyeon Bae, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Autoimmune Hepatitis (AIH) is a chronic progressive liver disease of unknown cause, characterized by circulating autoantibodies and hyperglobulinemia. Patients with AIH often have other…
Abstract Number: 702 • 2014 ACR/ARHP Annual Meeting
Protein Losing Enteropathy in Systemic Lupus Erythematosus
Doo-Ho Lim, Seung-Hyn Bae, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Protein losing enteropathy (PLE), characterized by severe hypoalbuminemia and edema, is rare manifestation of systemic lupus erythematosus (SLE). The study was proposed to identify…
Abstract Number: 701 • 2014 ACR/ARHP Annual Meeting
How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study
Isabelle Kloubert¹, Gamal Chehab¹, Jutta Richter², Rebecca Fischer-Betz³, Ralph Brinks² and Matthias Schneider¹, ¹Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ³Department of Rheumatology, University of Düsseldorf, Düsseldorf, Germany
Background/Purpose Physical activity (PA) plays a decisive role in primary and secondary prevention in various domains of medicine. Our examination aimed to determine association PA…
Abstract Number: 700 • 2014 ACR/ARHP Annual Meeting
Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease
Ofir Elalouf¹, Elizabeth Fireman², David Levartovsky¹, Ilana Kaufman¹, Ori Rogovski³, Ori Elkayam¹, Dan Caspi¹ and Daphna Paran¹, ¹Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ²Pulmonary and Allergic diseases, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ³Internal Medicine ward, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background/Purpose In a previous study, performed 9±3.6 years ago 74 asymptomatic patients with systemic lupus erythematosus (SLE) and or antiphospholipid syndrome (APS) who fulfilled the…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 718 • 2014 ACR/ARHP Annual Meeting
Safety of Gardasil® Vaccine in Systemic Lupus Erythematosu, Trial Update
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar^4,5, Ardella Magee⁶, Harpreet Sagar², Malini Venkatram⁷ and Robert Sokol⁸, ¹Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ²Internal Medicine/Rheumatology, Wayne State University, Detroit, MI, ³Wayne State University, Detroit, MI, ⁴Clinical Research Center, Wayne State University, Detroit, MI, ⁵CMED medical student,, Central Michigan University College of Medicine, Mount Pleasant, MI, ⁶Clinical Research Center, Wayne State University, Detroit, MI, ⁷Division of Rheumatology, Wayne State University, Detroit, MI, ⁸Obstetrics and Gynecology, Wayne State University, Detroit, MI
Background/Purpose: Cervical neoplasia is increased in women with SLE presumably due to cervical infection with oncogenic Human Papillomavirus (HPV) types which persist in an immunosuppressed…
Abstract Number: 717 • 2014 ACR/ARHP Annual Meeting
Comparison of Responsiveness of Lupus Impact Tracker with Lupus Quality of Life to Selena Responder Index
Hervé Devilliers¹, Narender Annapureddy², Winston Sequeira³, Joel A Block⁴ and Meenakshi Jolly², ¹Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³rush university, chicago, IL, ⁴Rush University, Chicago, IL
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…
Abstract Number: 716 • 2014 ACR/ARHP Annual Meeting
Simple Disease Assessment for People with Lupus Erythematosus
Meenakshi Jolly¹, Winston Sequeira², Sergio Toloza³, Ana M. Bertoli⁴, Luis M. Vilá⁵, Ivana Blazevic⁶, Ioana Moldovan⁷, Karina D Torralba⁸, Berna Goker⁹, Josiane Bourré-Tessier¹⁰, Sandra V. Navarra¹¹, Daniel Wallace¹², Michael H. Weisman¹³, Ann E. Clarke¹⁴, Chi Chiu Mok¹⁵ and Joel A. Block¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University, Chicago, IL, ³Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ⁴Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁶University of Buenos Aires, Buenos Aries, Argentina, ⁷Rheumatology, Beaver Medical Group, Redlands, CA, ⁸University of Southern California, LA, CA, ⁹Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹⁰Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²UCLA, LA, CA, ¹³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁵Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: Community rheumatologists treating patients with Systemic Lupus Erythematosus (SLE) typically lack user-friendly tools to effectively track SLE disease activity. Current disease activity tools in…
Abstract Number: 715 • 2014 ACR/ARHP Annual Meeting
The REAL Life with Lupus Study: Developing a Patient Reported Outcome Measure for Use in Clinical Trials and Clinical Care
R. Paola Daly¹, Sarah Gilman², Joan T. Merrill³, Leslie M. Hanrahan⁴, Alisha Ladenburg² and Anca Askanase⁵, ¹Research & Education, Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington, DC, ³Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Education & Research, Lupus Foundation of America, Washington, DC, ⁵Columbia University Medical Center, New York, NY
Background/Purpose: The goal of this study is to better understand how people with systemic lupus erythematosus (SLE) in the United States experience the disease. Results…
Abstract Number: 714 • 2014 ACR/ARHP Annual Meeting
The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study
Majed Khraishi¹, Rana Aslanov², Sanjay Dixit³, Ramin Yazdani⁴, Vandana Ahluwalia⁵ and Sarah Khraishi⁶, ¹Nexus Clinical Research, St John's, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Clare' Mercy Hospital, St. John's, NF, Canada, ⁵Rheumatology, William Osler Health Center, Brampton, ON, Canada, ⁶NL Research Technologies (NLRT), St. John's, NF, Canada
Background/Purpose In our centre, new tools for the assessment of SLE activity: the Lupus Activity Scoring Tool (LAST) and Clinical Lupus Activity Scoring Tool (C-LAST)…
Abstract Number: 713 • 2014 ACR/ARHP Annual Meeting
Lupuspro Is Responsive to Changes in Disease Activity over Time
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcome (PRO) tools are important to understand, educate, manage, and follow patients with systemic lupus erythematosus (SLE). Disease targeted PRO for SLE…
Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Rachel Meacock¹, Mark Harrison², Kathleen McElhone³, Janice Abbott⁴, Sahena Haque⁵, Ian N. Bruce⁶ and Lee- Suan Teh⁷, ¹Centre for Health Economics, The University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Royal Blackburn Hospital, Blackburn, United Kingdom, ⁴University of Central Lancashire, Preston, United Kingdom, ⁵University Hospital of South Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁷Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…
Abstract Number: 711 • 2014 ACR/ARHP Annual Meeting
Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare?
Kathleen McElhone¹, Jane Burnell², Chris Sutton², Janice Abbott³, Peter Lanyon⁴, Anisur Rahman⁵, Chee-Seng Yee⁶, Mohammed Akil⁷, Yasmeen Ahmad⁸, Ian Bruce⁹, Caroline Gordon¹⁰ and Lee-Suan Teh¹¹, ¹Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²School of Health, University of Central Lancashire, Preston, United Kingdom, ³University of Central Lancashire, Preston, United Kingdom, ⁴Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁵Centre for Rheumatology Research, University College London, London, United Kingdom, ⁶Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ⁷Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, ⁸Department of Rheumatology, Peter Maddison Research Centre, Bangor, United Kingdom, ⁹Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ¹⁰Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹¹Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose With improving survival in SLE patients, patient-reported health-related quality of life (HRQoL) has become an important outcome. The LupusQoL is a disease-specific patient-derived HRQoL measure…
Abstract Number: 710 • 2014 ACR/ARHP Annual Meeting
Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis
Luis J. Jara¹, Nahim Barron², Jesús Arenas-Osuna³, Arturo Vélazquez-García⁴, Arturo González-Zúñiga⁴, Miguel A Saavedra⁵ and Pilar Cruz-Domínguez⁶, ¹Direction of Education and Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ²General Surgery, Hospital de Especialidades Centro Médico La Raza, México, Mexico, ³Division of Education, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁴General Surgery, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁵Reumathology, Hospital de Especialidades Centro Médico La Raza, Mexico, Mexico, ⁶Division of Research, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Background/Purpose Acute presentation of severe autoinmune thrombocytopenia, and hemolytic anemia in systemic lupus erythematosus (SLE) is associated with high mortality. Splenectomy is the second line…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].